Search

Author/Creator Armuzzi, A

1. A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS. (7th March 2023)

Authors:
Sands, B E; Feagan, B; Gibble, T H; Traxler, K A; Morris, N; Li, X; Schreiber, S; Jairath, V; Armuzzi, A; Jones, J
Journal:
Journal of the Canadian Association of Gastroenterology
Issue:
Volume 6(2023)Supplement 1
Page Start:
16
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN'S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE. (15th March 2019)

Authors:
Panaccione, R; Colombel, J; Bossuyt, P; Baert, F; Vanasek, T; Danalioglu, A; Novacek, G; Armuzzi, A; Reinisch, W; Johnson, S; Buessing, M; Neimark, E; Petersson, J; Robinson, A M; Thakkar, R B; Lee, W; Skup, M; D'Haens, G
Journal:
Journal of the Canadian Association of Gastroenterology
Issue:
Volume 2(2019)Supplement 2
Page Start:
136
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. AODWE-008 Multicentre ecco collaborative group study to evaluate the need for re-intervention following multimodal treatment in crohn`s disease with perianal fistula. (17th June 2017)

Authors:
Black, C; Pugliese, D; Sahnan, K; Hart, A; Fiorino, G; Armuzzi, A; Katsanos, K; Christodoulou, D; Selinger, C; Maconi, G; Kopylov, U; Bosca-Watts, M; Karmiris, K; Davidov, Y; P, P Ellul; Whitehead, E; Ben-Horin, S; Danese, S; Fearnhead, N; Sebastian, S
Journal:
Gut
Issue:
Volume 66(2017)Supplement 2
Page Start:
A124
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. (16th January 2018)

Authors:
Kopylov, U; Verstockt, B; Biedermann, L; Sebastian, S; Pugliese, D; Sonnenberg, E; Steinhagen, P R; Arebi, N; Ron, Y; Kucharzik, T; Roblin, X; Ungar, B; Bar-Gil Shitrit, A; Ardizzone, S; Molander, P; Coletta, M; Peyrin-Biroulet, L; Bossuyt, P; Avni-Biron, I; Tsoukal, E I
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S029
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. (16th January 2018)

Authors:
Sands, B E; Moss, A C; Armuzzi, A; Marshall, J K; Lindsay, J O; Sandborn, W J; Danese, S; Tsilkos, K; Lawendy, N; Zhang, H; Friedman, G S; Chan, G; Krichbaum, D W; Su, C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S049
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. DOP065 Long-term cost-effectiveness of tight control for Crohn's disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial. (16th January 2018)

Authors:
Panaccione, R; Colombel, J -F; Bossuyt, P; Baert, F; Vanasek, T; Danalioglu, A; Novacek, G; Armuzzi, A; Reinisch, W; Johnson, S; Buessing, M; Neimark, E; Petersson, J; Robinson, A M; Thakkar, R B; Lee, W -J; Skup, M; D'Haens, G
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S074
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. DOP071 Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn's disease: data from CALM. (16th January 2018)

Authors:
Panaccione, R; Colombel, J -F; Bossuyt, P; Baert, F; Vanasek, T; Danalioglu, A; Novacek, G; Armuzzi, A; Reinisch, W; Neimark, E; Petersson, J; Robinson, A M; Thakkar, R B; Chen, N; Skup, M; Lee, W -J; D'Haens, G
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S078
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. DOP34 Long-term outcome of Acute Severe Ulcerative Colitis responsive to intravenous steroid: A multicenter study of the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). (27th May 2021)

Authors:
Festa, S; Scribano, M L; Aratari, A; Bezzio, C; Principi, M; Pugliese, D; Ribaldone, D G; Furfaro, F; Mocci, G; Spagnuolo, R; Vernia, P; Costa, F; Cosintino, R; De Biasio, F; Saibeni, S; Armuzzi, A; Papi, C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S072
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. DOP42 Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. (30th January 2023)

Authors:
Chaparro, M; Armuzzi, A; Irving, P M; Allez, M; Dubinsky, M C; Sands, B E; Goetsch, M; Wang, W; Shan, K; Woolcott, J; Bartolome, L; Wosik, K; Panaccione, R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗